Involvement of κ-Opioid and Endocannabinoid System on Salvinorin A-Induced Reward

Biological Psychiatry

Volumn 63, Issue 3, 2008, Pages 286-292

  Braida, Daniela ^a   Limonta, Valeria ^a   Capurro, Valeria ^a   Fadda, Paola ^b   Rubino, Tiziana ^c   Mascia, Paola ^b   Zani, Alessia ^a   Gori, Enzo ^a   Fratta, Walter ^b   Parolaro, Daniela ^c   Sala, Mariaelvina ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c DBSF   (Italy)

Author keywords

opioid receptor; Conditioned place preference; dopamine; microdialysis; self administration; SR 141716A

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; KAPPA OPIATE RECEPTOR; NORBINALTORPHIMINE; RIMONABANT; SALVINORIN A;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SELF ADMINISTRATION; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REWARD; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DITERPENES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; ENDOCANNABINOIDS; MALE; MICRODIALYSIS; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, OPIOID, KAPPA; REWARD; SELF ADMINISTRATION;

EID: 38049032934     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.07.020     Document Type: Article

References (47)

1. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., et al. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99 (2002) 11934-11939
2. Sheffler D.J., and Roth B.L. Salvinorin A: The "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24 (2003) 107-109
3. Chavkin C., Sud S., Jin W., Stewart J., Zjawiony J.K., Siebert D.J., et al. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308 (2004) 1197-1203
4. Yan F., and Roth B.L. Salvinorin A: A novel and highly selective kappa-opioid receptor agonist. Life Sci 75 (2004) 2615-2619
5. Prisinzano T.E. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78 (2005) 527-531
6. Siebert D.J. Salvia divinorum and salvinorin A: New pharmacologic findings. J Ethnopharmacol 43 (1994) 53-56
7. Gonzalez D., Riba J., Bouso J.C., Gomez-Jarabo G., and Barbanoj M.J. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85 (2006) 157-162
8. Turner D.M. Salvinorin: The Psychedelic Essence of Salvia Divinorum (1996), Panther Press, San Francisco
9. Rothman R.B., Murphy D.L., Xu H., Godin J.A., Dersch C.M., Partilla J.S., et al. Salvinorin a: Allosteric interactions at the mu opioid receptor. J Pharmacol Exp Ther 320 (2007) 801-810
10. Capasso R., Borrelli F., Capasso F., Siebert D.J., Stewart D.J., Zjawiony J.K., et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 18 (2006) 69-75
11. Mowry M., Mosher M., and Briner W. Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs 35 (2003) 379-382
12. McCurdy C.R., Sufka K.J., Smith G.H., Warnick J.E., and Nieto M.J. Antinociceptive profile of salvinorin A, a structurally uniquekappa opioid receptor agonist. Pharmacol Biochem Behav 83 (2006) 109-113
13. Ansonoff M.A., Zhang J., Czyzyk T., Rothman R.B., Stewart J., Xu H., et al. Antinociceptive and hypothermic effects of salvinorin A are abolished in a novel strain of KOR-1 KO mice. J Pharmacol Exp Ther 318 (2006) 641-648
14. Fantegrossi W.E., Kugle K.M., Valdes III L.J., Koreeda M., and Woods J.H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behav Pharmacol 16 (2005) 627-633
15. Carlezon Jr. W.A., Beguin C., DiNieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316 (2006) 440-447
16. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., and Kreek M.J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179 (2005) 551-558
17. Butelman E.R., Harris T.J., and Kreek M.J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology (Berl) 172 (2004) 220-224
18. Mendizábal V., Zimmer A., and Maldonado R. Involvement of κ/Dynorphin system in WIN 55,212-2 self-Administration in mice. Neuropsychopharmacology 31 (2006) 1957-1966
19. Maldonado R., Valverde O., and Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29 (2006) 225-232
20. Braida D., Pozzi M., Cavallini R., and Sala M. 3,4 methylenedioxymethamphetamine (ecstasy) impairs eight-arm radial maze performance and arm entry pattern in rats. Behav Neurosci 116 (2002) 298-304
21. Braida D., Pozzi M., Cavallini R., and Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system. Neuroscience 104 (2001) 923-926
22. Braida D., Virag W., Ottonello F., Inghilterra S., Gori E., and Sala M. A novel method for self-administering addicting drugs intracerebroventricularly in a free-choice procedure. Brain Res Brain Res Protoc 3 (1998) 135-141
23. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, New York
24. Bert L., Favale D., Jego G., Greve P., Guilloux J.P., Guiard B.P., et al. Rapid and precise method to locate microdialysis probe implantation in the rodent brain. J Neurosci Methods 140 (2004) 53-57
25. Braida D., Iosue S., Pegorini S., and Sala M. Δ9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol 511 (2005) 75-76
26. 1-cannabinoid receptor involvement. Psychopharmacology 190 (2007) 441-448
27. Valdes L.J., Diaz J.L., and Paul A.G. Ethnopharmacology of ska Maria Pastora (Salvia divinorum). J Ethnopharmacol 7 (1983) 287-312
28. Braida D., Pozzi M., Parolaro D., and Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol 413 (2001) 227-234
29. Braida D., and Sala M. Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 136 (2002) 1089-1092
30. Koob G.F. The reward system and cocaine abuse. In: Korenman S.G., and Barchas J.D. (Eds). Biological Basis of Substance Abuse (1993), Oxford Univ. Press, New York 339-354
31. Shippenberg T.S., and Herz A. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu-kappa-opioid agonists. Brain Res 436 (1987) 169-172
32. Bals-Kubik R., Herz A., and Shippenberg T.S. Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology 98 (1989) 203-206
33. Mori T., Nomura M., Nagase H., Narita M., and Suzuki T. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820 on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology 161 (2002) 17-22
34. Suzuki T., Shiozaki Y., Masukawa Y., Misawa M., and Nagase H. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 58 (1992) 435-442
35. Iwamoto E.T. Characterization of dynorphin A(1-17)-induced place preference in rats. NIDA Res Monogr 95 (1989) 308-309
36. Marinelli M., Barrot M., Simon H., Oberlander C., Dekeyne A., Le Moal M., and Piazza P.V. Pharmacological stimuli decreasing nucleus accumbens dopamine can act as positive reinforcers but have a low addictive potential. Eur J Neurosci 10 (1998) 3269-3275
37. Bellissant E., Denolle T., Sinnassamy P., Bichet D.G., Giudicelli J.F., Lecoz F., et al. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers. J Pharmacol Exp Ther 278 (1996) 232-242
38. McLaughlin J.P., Land B.B., Li S., Pintar J.E., and Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 31 (2006) 787-799
39. Wang Y., Tang K., Inan S., Siebert D., Holzgrabe U., Lee D., et al. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312 (2005) 220-230
40. Hanes K.R. Antidepressant effects of the herb Salvia divinorum: A case report. J Clin Psychopharmacol 21 (2001) 634-635
41. Heimer L., Zahm D.S., Churchill L., Kalivas P.W., and Wohltmann C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 41 (1991) 89-125
42. Di Chiara G. A motivational learning hypothesis of the role of dopamine in compulsive drug use. J Psychopharmacol 12 (1998) 54-67
43. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 375 (1999) 13-30
44. Sandi C., Borrell J., and Guaza C. Involvement of kappa type opioids on ethanol drinking. Life Sci 42 (1988) 1067-1075
45. Funada M., Suzuki T., Narita M., Misawa M., and Nagase H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 32 (1993) 1315-1323
46. Glick S.D., Maisonneuve I.M., Raucci J., and Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681 (1995) 147-152
47. Hahn B., Stolerman I.P., and Shoaib M. Kappa-opioid receptor modulation of nicotine-induced behaviour. Neuropharmacology 39 (2000) 2848-2855